All News

PLT012 demonstrates its potential against multiple tumors with unmet medical needs.

Dose rounding within an acceptable range can provide cost savings and minimize waste, but requires careful interprofessional collaboration and patient education.

According to the report, 75% of survey participants expect pharmacists to oversee these therapies and 58% expect Medicare will require pharmacist involvement.

Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.

Experts discuss advancements in hormone receptor–positive/HER2-negative breast cancer treatment while addressing safety, diversity, and fertility challenges.

Navtemadlin has demonstrated meaningful efficacy and safety as a monotherapy or combination treatment in various preclinical and clinical trials.

Results suggest that patients commonly receive more than 5 days of treatment, which could be an opportunity for an antimicrobial stewardship initiative.

Pharmacists are essential members of the patient care team, leveraging technology like automated IV compounding to standardize processes.

The progress made in areas like scope expansion and reimbursement is encouraging, suggesting a growing recognition of pharmacists’ value within the health care system.

Pharmacists play a crucial role in promoting the appropriate use of broad-spectrum antibiotics to prevent antimicrobial resistance and improve patient outcomes.

The 23-valent pneumococcal polysaccharide vaccine (PPSV23, Pneumovax 23; Merck Sharp & Dohme Corp) demonstrates effective reductions in the risk of hospitalizations.

This builds off prior data that showed safety and efficacy of CD19 and CD22 chimeric antigen receptor (CAR)-T cell therapy in children with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL).

Further research is needed to identify the influence of high-dose vitamin D supplementation among vitamin D–deficient populations.

Sonja Zweegman, MD, PhD, explains the improvements in minimum residual disease negativity found after treatment with daratumumab and the VRd regimen in patients with newly-diagnosed multiple myeloma who are transplant-ineligible.

Luca Bertamini, MD highlights the potential clinical implications of using circulating tumor cells as a biomarker in patients with newly-diagnosed multiple myeloma.

The primary challenge facing rural pharmacies include recruitment and retention of staff, the need for pharmacists to handle multiple roles and expertise, and the impact of burnout and stress.

Adults with epilepsy are underrepresented in most CBD trials, including common etiologies.

The phase 3 CEPHEUS trial demonstrated that adding daratumumab (DARA) to the VRd regimen significantly improves minimal residual disease negativity, progression-free survival, and overall response in transplant-ineligible or transplant deferred patients with newly diagnosed multiple myeloma, establishing a new standard of care.

The GMMG-HD7 trial evaluated the addition of isatuximab to standard induction therapy in patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation, demonstrating significantly higher rates of minimal residual disease negativity and improved progression-free survival (PFS).

Brain Health is an emerging research topic, but there is not a standard outcome measure.

Snehal Bhatt emphasizes the need for patient-specific risk assessment and a thoughtful approach to balancing aspirin's benefits and bleeding risks as new treatment options become available.

Although challenges and obstacles persist, artificial intelligence could help rural and smaller pharmacies close gaps in care.

If approved, the treatment will be the first and only once-daily, oral selective somatostatin receptor type 2 nonpeptide agonist available for acromegaly.

Pharmacists play a key role in vaccination efforts to prevent respiratory illnesses.

Ira Zackon, MD explains his analysis of bispecific antibody utilizaton for relapsed or refractory multiple myeloma in community oncology centers.

Robert Rifkin, MD, FACP, discusses multiple abstracts featuring drugs demonstrating efficacy in patients with relapsed/refractory multiple myeloma.

Shirley D'Sa, MD, highlights the long-term efficacy and tolerability of zanubrutinib in patients with Waldenström macroglobulinemia, as seen in the long-term extension of ASPEN.

The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).